Peak Retirement Planning Inc. Invests $837,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Peak Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,066 shares of the biopharmaceutical company’s stock, valued at approximately $837,000.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC grew its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP boosted its stake in Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock worth $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after purchasing an additional 749,047 shares during the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at $1,789,254,000. Finally, Northern Trust Corp raised its holdings in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $107.37 on Friday. The stock has a market cap of $133.56 billion, a PE ratio of 290.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The stock has a 50-day moving average of $105.27 and a 200-day moving average of $100.30. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.32) earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.94%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,929 shares of company stock worth $5,644,780. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GILD shares. Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.